Paul A. Friedman, M.D. has served as Chairman of the Board of Directors and as Chief Executive Officer since July 2016. Dr. Friedman served as a member of Synta Pharmaceuticals Corp.’s Board of Directors from March 2014 until April 2016. Dr. Friedman served as the Chief Executive Officer and a Director of Incyte Corporation from November 2001 until his retirement in January 2014. From 1994 to 1998, he served as President of Research & Development for the DuPont-Merck Pharmaceutical Company, and from 1998 to 2001, as President of DuPont Pharmaceuticals Research Laboratories, a wholly-owned subsidiary of the DuPont Company. From 1991 to 1994, he served as Senior Vice President at Merck Research Laboratories. Prior to his tenures at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. Dr. Friedman currently sits on the Board of Directors of Cerulean Pharma Inc., a publicly traded pharmaceutical company, Verastem, Inc., a publicly traded pharmaceutical company, Incyte Corporation, a publicly traded pharmaceutical company, and Gliknik, Inc. He has previously served on the Board of Directors of Auxilium Pharmaceuticals Inc., a publicly traded pharmaceutical company, and Durata Therapeutics, Inc., a publicly traded pharmaceutical company. Dr. Friedman received his A.B. in Biology from Princeton University and his M.D. from Harvard Medical School.
Rebecca Taub, M.D. has served as President of Research & Development since July 2019 and continues to serve as Chief Medical Officer and a member of our Board of Directors. She served as Executive Vice President, Research & Development, Chief Medical Officer and as a member of our Board of Directors from July 2016 to July 2019. Prior to joining Madrigal, Dr. Taub served as Senior Vice President, Research and Development of VIA Pharmaceuticals from 2008 to 2011 and as Vice President, Research, Metabolic Diseases at Hoffmann-La Roche from 2004 to 2008. In those positions, Dr. Taub oversaw clinical development and drug discovery programs in cardiovascular and metabolic diseases including the conduct of a series of Phase I and II proof of concept clinical trials. Dr. Taub led drug discovery, including target identification, lead optimization and advancement of preclinical candidates into clinical development. From 2000 through 2003, Dr. Taub worked at Bristol-Myers Squibb Co. and DuPont Pharmaceutical Company in a variety of positions, including Executive Director of CNS and metabolic diseases research. Before becoming a pharmaceutical executive, Dr. Taub was a tenured Professor of Genetics and Medicine at the University of Pennsylvania. Dr. Taub is the author of more than 120 research articles. Before joining the faculty of the University of Pennsylvania, Dr. Taub served as an Assistant Professor at the Joslin Diabetes Center of Harvard Medical School, Harvard University and an associate investigator with the Howard Hughes Medical Institute. Dr. Taub received her M.D. from Yale University School of Medicine and B.A. from Yale College.
Alex Howarth is Madrigal’s Chief Financial Officer and joined the company in May 2021, bringing more than 25 years’ experience in healthcare finance and operational roles.
Prior to joining Madrigal, Mr. Howarth served as Chief Operating Officer at Akcea Therapeutics, a commercial stage biopharmaceutical company acquired by Ionis in October 2020. In this role Mr Howarth was responsible for corporate strategy, business development, management of stakeholder alliances, legal and compliance, as well as product supply chain. Previously, Mr Howarth served as President and Chief Financial Officer at Lycera Corp, a development stage biotechnology company. Prior to joining Lycera, Mr Howarth was Chief Financial Officer of moksha8 and during his tenure he played a leading role in defining organizational strategy to build the company and establish its global business. Prior to this, Mr. Howarth was Chief Business Officer at Vitae Pharmaceuticals. Previously, Mr. Howarth held senior positions at GSK including Head, Venture Partnerships, focused on partnering GSK’s clinical assets globally and as Senior Director, Worldwide Business Development, executing licensing transactions across all phases of development in diverse therapeutic areas. Before this, he worked at KPMG, London where he qualified as a chartered accountant.
Mr. Howarth received his BSc degree in biochemistry from the University of Bath, UK, and conducted neuroscience and molecular biology research at Merck and Celltech.
Brian J. Lynch has served as Senior Vice President and General Counsel of Madrigal since February of 2019. During the 29 years before joining Madrigal, Mr. Lynch engaged in private practice with leading law firms headquartered in Philadelphia, Washington, DC and Silicon Valley, principally with Hogan Lovells and Morgan, Lewis & Bockius. A significant portion of his private practice career was focused on representing life sciences companies. Mr. Lynch began his legal career in public service at the Securities and Exchange Commission’s Division of Corporation Finance in Washington, DC from 1987-1990. Mr. Lynch earned a Bachelor’s degree, Accounting and English, from La Salle University and a Juris Doctor degree from the Temple University School of Law.
Remy Sukhija has served as Senior Vice President and Chief Commercial Officer since April 2020. Mr. Sukhija has over 25 years of commercial experience spanning leadership roles in large pharmaceutical, mid-size biotech, and venture-backed small biotech companies. Mr. Sukhija has launched 11 pharmaceutical products in specialty, primary care and rare disease markets. From January 2017 to March 2020, Mr. Sukhija served as Senior Vice President, North America, for Otsuka Pharmaceutical with direct responsibility for all Commercial Operations, Market Access and Government Policy functions. At Otsuka, Mr. Sukhija oversaw the launch of JYNARQUE® in the specialty renal market. From May 2015 to December 2016, Mr. Sukhija served as Chief Operating Officer for Merganser Biotech, Inc., a venture-backed biotech, and as Executive Board Member of Merganser Biotech Australia Pty. Ltd., its wholly owned subsidiary. From April 2010 to April 2015, Mr. Sukhija served as Vice President and Business Unit Head for Biogen. While at Biogen, Mr. Sukhija was responsible for building a commercial organization from the ground-up to launch two first-in-class hemophilia therapies (ALPROLIX® and ELOCTATE®), and he was a member of the U.S. Leadership Team responsible for the $5 billion per year U.S. affiliate and the launch of Tecfidera® for multiple sclerosis. Before joining Biogen, Mr. Sukhija held various US Marketing, Global Marketing and EU-based General Management positions of increasing responsibility for Pfizer from 2001 to 2010. Mr. Sukhija started his career in pharmaceutical sales at GlaxoSmithKline in 1993. Mr. Sukhija earned his degree in business from The University of Akron.